QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Forecast, Price & News

$4.03
+0.12 (+3.07%)
(As of 09/28/2023 ET)
Compare
Today's Range
$3.90
$4.10
50-Day Range
$3.10
$4.16
52-Week Range
$1.88
$4.70
Volume
55,289 shs
Average Volume
58,450 shs
Market Capitalization
$35.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Neoleukin Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
86.1% Upside
$7.50 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Neoleukin Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$1.31 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

439th out of 969 stocks

Pharmaceutical Preparations Industry

194th out of 455 stocks


NLTX stock logo

About Neoleukin Therapeutics (NASDAQ:NLTX) Stock

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NLTX Price History

NLTX Stock News Headlines

Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity
Guess What The Fed Is Doing To Your Money Now?
For years, the Federal Reserve has been printing mountains of money jacking up interest rates and driving the U.S. into a recession. And just a few weeks ago, they did something even more disturbing. And hardly anyone is talking about it. Yet this could harm you more than money printing and interest rates. It made a frightening power grab of the U.S. dollar, and it could cause you to lose control of your cash.
Neurogene, Neoleukin Announce Planned Merger
NLTX Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics (NLTX) Receives a Hold from Mizuho Securities
See More Headlines
Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NLTX
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$7.50
Forecasted Upside/Downside
+86.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-57,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.08 per share

Miscellaneous

Free Float
8,665,000
Market Cap
$35.46 million
Optionable
Optionable
Beta
1.17
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Donna M. Cochener-Metcalfe J.D. (Age 48)
    Gen. Counsel, Interim CEO & Corp. Sec.
    Comp: $403.75k
  • Dr. David Baker M.D.
    Ph.D., Co-Founder
  • Mr. Sean Michael Smith (Age 37)
    Interim Chief Financial Officer













NLTX Stock - Frequently Asked Questions

Should I buy or sell Neoleukin Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares.
View NLTX analyst ratings
or view top-rated stocks.

What is Neoleukin Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year target prices for Neoleukin Therapeutics' shares. Their NLTX share price forecasts range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for NLTX
or view top-rated stocks among Wall Street analysts.

How have NLTX shares performed in 2023?

Neoleukin Therapeutics' stock was trading at $2.5450 at the start of the year. Since then, NLTX shares have increased by 58.3% and is now trading at $4.03.
View the best growth stocks for 2023 here
.

Are investors shorting Neoleukin Therapeutics?

Neoleukin Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 43,000 shares, a decrease of 63.5% from the August 31st total of 117,900 shares. Based on an average daily volume of 60,700 shares, the short-interest ratio is currently 0.7 days. Currently, 0.1% of the shares of the stock are sold short.
View Neoleukin Therapeutics' Short Interest
.

When is Neoleukin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our NLTX earnings forecast
.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.55.

When did Neoleukin Therapeutics' stock split?

Neoleukin Therapeutics's stock reverse split on the morning of Monday, September 25th 2023. The 1-5 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.19%), Western Standard LLC (1.96%), BlackRock Inc. (1.13%) and Privium Fund Management B.V. (0.27%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Robert Ho and Sean Michael Smith.
View institutional ownership trends
.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $4.03.

How much money does Neoleukin Therapeutics make?

Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $35.46 million. The company earns $-57,560,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486.

This page (NASDAQ:NLTX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -